EMA: Updated Q&A on Nitrosamines and Step 2-Template
The European Medicines Agency (EMA) has published a revised version 9 of its Q&A on nitrosamines for marketing authorisation holders dated 20 May 2022.
The revision includes an update of the following questions:
- Q&A 4 was updated to reflect the update of the Guidance on root causes and risk factors for contamination with nitrosamines.
- Q&A 8 was updated on the requirements and conduct of confirmatory testing.
- Q&A 15 includes new dossier requirements to allow testing of intermediates, raw materials or active substances under certain circumstances.
- The new Q&A 20 includes clarifications on the regulatory steps to be taken in dealing with scenario A cases, i.e., after the identification of nitrosamine with exceeded tolerable intake.
- Q&A 10 now includes these Nitrosamines with their acceptable intake:
- N-nitrosomethylphenidate, (1300 ng/day)
- N-nitrosopiperidine, (1300 ng/day)
- N-nitrosorasagilene, (18 ng/day)
- 7-Nitroso-3-(trifluoromethyl)-5,6,7,8 tetrahydro[1,2,4]triazolo-[4,3-a]pyrazine, (37 ng/day)
- N-nitroso-1,2,3,6-tetrahydropyridine, (37 ng/day)
- N-nitrosonortriptyline, (8 ng/day)
- N-methyl-N-nitrosophenethylamine, (8 ng/day)
along with guidance on use of Ames test.
The new Step 2-template can be found here.
Source:
EMA: Website on Nitrosamine impurities
EMA: Q&A for marketing authorization holders/applicants on the CHMP Opinion for the Article 5(3) of Regulation (EC) No 726/2004 referral on nitrosamine impurities in human medicinal products
Meet the GMP Compliance Adviser
The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business.
The demo access is non-binding and ends automatically.
You may also be interested in the following articles:
